Thus, a 6-month treatment with fluoxetine (20 mg/day) attenuated the secretion of IL-17 by stimulated CD4+ and CD8+ T-cells in relapsing–remitting MS patients with depression (27). The gene discussed is IL17A; the disease is myeloid sarcoma.